Kevin retweeted
$PRME Danaher just put prime editing and base editing on the shelf.
IDT + Aldevron, Nov 4:
• PE Ultra prime editor mRNA, chemically modified Alt-R pegRNAs, and a pegRNA design tool
• Six stocked ABE8e base editors, plus a kit to screen all six at once
• 20 µg to 1 mg in stock, larger runs custom
Research grade. No CGMP timeline announced.
What it replaces: sourcing a plasmid, making your own mRNA, and working out guide design by trial and error.
Stocked inventory is a forecast.
Danaher builds those with a spreadsheet, not a press release.
Same two companies manufactured the components for the world's first mRNA-based personalized CRISPR therapy.
Every target proven in an animal needs a human therapeutic license to go further.
UBC is becoming a world leader in acedemic led drug development!
"Leading an initiative known as Canada's Immuno-Engineering and Biomanufacturing Hub, which includes involvement from many other academic institutions, and aims to quicken drug development"
biv.com/news/technology/bc-c…
6
391
Kevin retweeted
Arrowhead Pharmaceuticals ($ARWR) is the weirdest company in the world. 🧬
In 2011, they bought a $1 billion tech portfolio for "pennies" while drinking pints in a London pub.
Now, they are silencing genes to save lives.
Here is the story of the ultimate Biotech Renaissance. 🧵
#BioTech #ARWR #Investing #Genomics
1/11
Kevin retweeted
4/ Yesterday Capstan Broke the Trend
AbbVie paid $2.1B for Capstan’s in-vivo CAR-T at Phase 1.
That’s 10–15x the typical single-asset price tag.
Why?
Because Capstan isn’t a product.
It’s a platform.
fiercebiotech.com/biotech/ab…
Kevin retweeted
Dr. Pieter Cullis is changing the world, one tiny lipid nanoparticle at a time!
cihr-irsc.gc.ca/e/54321.html…

ALT Side-by-side "How it started / How it's going" meme. Left image (How it started): A black-and-white photo of a Dr. Cullis in the 1980s sitting at a desk using an old computer. The caption below reads: “Assembling lab gear in a coworker’s garage and offering free beer to staff on Fridays.” Right image (How it’s going): A recent photo of Dr. Cullis smiling in a modern lab. The caption below reads: “12 biotech companies. 100+ patents. Millions of lives saved by mRNA technology!"
Kevin retweeted
Interesting comments on extrahepatic targeting of LNPs from a pioneer in the field.
𝐅𝐫𝐨𝐦 𝐕𝐚𝐧𝐜𝐨𝐮𝐯𝐞𝐫: Professor Pieter Cullis and Jay Kulkarni, co-founders of NanoVation Therapeutics, discusses the next generation of lipid nanoparticle delivery.
Full video: biotechtv.com/post/nanovatio…
“First successful clinical correction of a mutation in DNA” achieved by an LNP delivered Base Editor $BEAM
Privileged to share initial data for BEAM-302 today in alpha-1 antitrypsin deficiency (AATD)!
AATD is a severe, progressive disease impacting both lung and liver function that affects 100,000 people in the US
globenewswire.com/news-relea…
12
931
Kevin retweeted
$ARWR some preclinical results of ARO-ALK7 (silencing with #Tirzepatide from $LLY). Investors need patience, but the opportunities for the #RNAi play in the obesity market are great in the long term. ir.arrowheadpharma.com/stati…
Kevin retweeted
$ARWR:
I bought $ARWR because I wanted more late stage companies with multiple drugs and multiple indications that could offer a lot of potential.
I bought because the valuation was way below my estimates
I bought because they have 2 later stage programs in cholesterol which are very competitive spaces. I am hopeful they can compete with other therapies in this space.
I bought because they have 2 early obesity programs that could be huge if they are successful. They offer the option of the upside at a much better valuation than other companies in this space that are over hyped.
I bought because they seem to have a sound management team and a good balance sheet.
I bought because I can buy more cheaper if the sector crashes, but I could also sell for big profits if the sector rallies. I like that I am not married to the company so I can be flexible if my strategy changes.
RIP to a gene therapy pioneer 🫡
Unfortuantly Ex-Vivo lentiviral gene insertion was a poor delivery tech to begin with. Requiring myeloablative conditioning, fertility risks, and CL2+ viral vector production.
In-Vivo LNP gene editing will be the holy grail imo.
Once valued at $10B, bluebird bio sold to private equity firms for $29M fiercepharma.com/pharma/once…
1
7
441
$ALLO Cema-cel vs. $GILD Yescarta in LBCL.
Comparable CR with lower side effects and longer duration.
Very impressive for an off the shelf CAR-T!
Full Ph1 ALPHA/ALPHA2 cema-cel data in @JCO_ASCO, demonstrating long-term durability of a 1x Tx in r/r #LBCL patients with our investigational allogeneic #CART and 100% CR in patients with low disease burden – the focus of our ALPHA3 trial in 1L. $ALLO @DrFredLocke
Learn more about cema-cel: ir.allogene.com/news-release…
6
517
$BMY looking to free up $2B for M&A.
$TGTX Briumvi and AzerCel would look very nice in their MS portfolio next to Zepovia (1st line oral).
Maybe MW told them to come back with more cash.
endpts.com/bristol-myers-lau…
Kevin retweeted
Big opportunity for a Duchenne gene therapy that actually works!
$SRPT CEO says demand for their gene therapy is overwhelming. Haven’t even dosed 5% of eligible patients.
Kevin retweeted
So wonderful to see Tim Harris’ book on biotech arrive from Amazon today!
This is a MUST read for anyone interested in the history of biotech!
Enjoy!!!

























